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Abstract
Objectives: To determine placental transfer of ketanserin and to assess the effect of serotonin-2 receptor blockade by ketanserin 
on serotonin- and phenylephrine-induced vasoconstriction. Study design: Five chronically instrumented pregnant ewes at 120 days 
gestation were injected with 20 mg ketanserin i.v., and fetal and maternal arterial samples were obtained at predetermined intervals 
to assess placental transfer. Maternal and fetal responses of blood flows and pressures were determined after injection of serotonin 
(20 fig/kg) or phenylephrine (10 Mg/kg) before and after ketanserin (0.7S mg/kg). Results: In the ewe, ketanserin is transferred across 
the placenta and reaches measurable levels in the fetal lamb. Ketanserin blocks the maternal and fetal serotonin-induced rise in 
arterial pressure, but not the serotonin-induced reduction in uterine blood flow. Conclusion: In the pregnant ewe,the serotonin- 
induced rise in maternal and fetal blood pressure is effectively antagonized by ketanserin, whereas the serotonin-induced reduction 
in uterine blood flow is not.
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1. Introduction
The circulation in untreated preeclamptic patients is 
characterized by an elevated blood pressure, reduced 
cardiac output, and an increased systemic vascular resis­
tance with reduced perfusion o f  the placenta and m ater­
nal organs including the kidney [1]. There is increasing 
evidence that preeclampsia is a trophoblast-dependent 
pathophysiological process that starts early in preg­
nancy and is mediated by platelet activation, caused by 
damaged or dysfunctional endothelium leading to vaso­
constriction [2,3].
Serotonin (5-hydroxytryptamine, 5-HT) is released 
following platelet aggregation and platelets are known 
to augment the effect o f other vasoconstrictors through 
the release o f serotonin [4]. Because platelet activation
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and aggregation are associated with release o f  serotonin, 
this vasoactive substance and its receptors may be 
involved in the pathophysiology o f  preeclampsia [5,6], 
The antihypertensive drug ketanserin (Ketensin®) is a 
selective antagonist o f serotonin receptors that belong to 
the 5-HT-2 category. Ketanserin lowers blood pressure 
through reduction o f peripheral vascular resistance, 
while cardiac output remains virtually unaltered [7]. In 
addition to its antihypertensive effect, ketanserin also 
blocks the serotonin-induced aggregation o f  platelets 
[8]. From  a theoretical point o f view, these pharm aco­
logic features make ketanserin an attractive choice for 
the antihypertensive treatm ent o f patients with pre­
eclampsia, and a number o f small clinical studies have 
been published [9-13], However, its potential use in 
pregnancy could be offset by unwanted side effects on 
the uteroplacental and fetal circulations, the latter 
depending on placental transfer and fetal sensitivity to 
the drug. There are limited experimental data in preg­
nant rats on the effects o f ketanserin on maternal hemo­
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dynamics and uteroplacental circulation [14], and no 
information on placental transfer is available.
The present study was designed to determine in 
chronically instrumented pregnant ewes the placental 
transfer o f ketanserin from the ewe to the fetal lamb, 
and to assess the effect o f blockade of serotonin-2 recep­
tors by ketanserin on serotonin- and phenylephrine- 
induced vasoconstriction.
2. Materials and methods
We studied five chronically instrumented pregnant 
Texel ewes with a median (range) weight o f 62 (59-69) 
kg at 120 (115-135) days o f gestation (term 145 days). 
Guidelines for the care and use o f the animals, approved 
by the University Animal Experiments Committee, were 
followed.
2.1. Surgical protocol
The animals were acclimatized in the animal research 
facility for at least 3 days before operation. Twelve 
hours prior to surgery the animals were taken off food, 
but water remained freely available. After premedica­
tion with ketamine (15 mg/kg bodyweight) and atropine 
(0.5 mg) i.m., anesthesia was induced with thiopen- 
talsodium (7-14  mg/kg) i.v. The ewe was intubated and 
ventilated, anesthesia was maintained with enflurane 2% 
in a 2:1 mixture of nitrous oxide and oxygen. Through 
a lower abdominal midline incision and a small incision 
in the uterus, the fetal hindlimbs were exteriorized. Poly­
ethylene catheters were introduced in both fetal femoral 
arteries and in one femoral vein and threaded into the 
distal aorta and vena cava, respectively. Fetal weight 
was estimated by palpation and the uterine incision was 
closed. A precalibrated electromagnetic flow probe, 
(IS10-S-A-0, Skalar, Delft, The Netherlands) o f appro­
priate size (ID 2.5-4.5 mm) was placed around the main 
uterine artery on the side o f the instrumented fetal lamb, 
and a uterine vein was catheterized through a side- 
branch. All catheters were tunnelled, exteriorized 
through a flank incision and secured in a pouch attached 
to the flank. A catheter was placed in a maternal carotid 
artery and vein through an incision in the neck. All 
catheters were flushed daily with a saline solution con­
taining amoxicillin (10 mg/ml), metronidazole (5 mg/ml) 
and heparin (100 U/ml).
2.2. Experimental protocol
Experiments were performed after at least 2 days of 
recovery with the ewes standing quietly in an individual 
cage with unlimited access to food and water. Maternal 
and fetal arterial pressures were measured using Gould 
Statham P 23 ID  pressure transducers. Pressures and 
uterine artery blood flow signals were recorded on a
Gould Brush 2800 recorder (Cleveland, USA), and 
stored on hard-disk with a sample frequency o f 1 Hz.
On the first experimental day we assessed placental 
transfer o f ketanserin. After a 30-min control period, a 
20-mg bolus o f ketanserin was slowly injected into the 
maternal vein. Fetal and maternal arterial samples (1 
ml) were obtained at 5, 30, 60, 120, 180, and 240 min 
after injection.
After immediate centrifugation, the plasma was 
stored at -20°C  until assay. Ketanserin concentrations 
were determined fluorometrically after high-perform­
ance liquid chromatography [15]. The minimum detec­
table concentration was 2.0 ng/ml.
In a second experiment, the efficacy o f blockade of 
serotonin-2 receptors and of a-l-adrenoreceptors by 
ketanserin was investigated. On consecutive days we 
measured responses after injection o f serotonin (20 
/¿g/kg) or phenylephrine (10 /¿g/kg) into either a m ater­
nal or a fetal vein, both in the control state and 30 min 
after intravenous injection o f a single dose o f ketanserin 
(0.75 mg/kg of maternal or estimated fetal weight). 
Before, during and after experiments maternal and fetal 
arterial samples (1 ml) were drawn for immediate blood 
gas analysis (ABL 3, Radiometer, Copenhagen, Den­
mark) and determination o f hemoglobin concentrations 
(OSM2, Radiometer, Copenhagen, Denmark) to verify 
maternal and fetal health throughout the experiment.
2.3. Data analysis
Ketanserin concentrations are presented as median 
values ( ±  ranges), all other variables as means 
(±  S.D.). We used Student’s /-test for paired samples to 
assess differences between test periods. A P-value of 
<0.05 was taken as the level of significance.
3. Results
All ewes and fetal lambs remained in good condition 
during the week after surgery and throughout the exper­
iments. Before the administration o f ketanserin to the 
ewe or the fetal lamb median (range) values of maternal 
and fetal pH were 7.42 (7.40-7.43) and 7.35 (7.33-7.38), 
respectively; after ketanserin values were similar, 7.41 
(7.40-7.43) and 7.34 (7.30-7.35), respectively. Median 
(range) estimated fetal weight was 2500 (1500-3500) g, 
not different from the median (range) birthweight o f 
2570 (1850-3850) g.
3.1. Placental transfer o f  ketanserin
Maternal and fetal arterial plasma concentrations 
following injection o f 20 mg of ketanserin into a m ater­
nal vein are presented in Fig. 1. The median half-life of 
ketanserin in the arterial circulation o f the ewe was 13 
min. Five minutes after injection of ketanserin the medi-
T.J. Schneider et al. / European Journal o f  Obstetrics & Gynecology and Reproductive Biology 68 (1996) 179-184 181
(min)
Fig. 1. Median concentrations of ketanserin (ng/ml) in maternal ( • )  
and fetal (O) arterial plasma following intravenous administration of 
20 mg ketanserin in five pregnant ewes.The minimal detectable con­
centration of ketanserin is indicated by the horizontal broken line. 
Numbers of samples with detectable levels between parentheses.
an maternal arterial concentration reached a peak value 
o f 153 ng/ml, with a wide range o f 105-588 ng/ml. Low 
median concentrations o f  6.1 ng/ml (range < 2 .0 -2 5 .4  
ng/ml) were dem onstrated in three o f five fetal lambs,
whereas no ketanserin was detected in two fetuses. Thir­
ty minutes after injection ketanserin was demonstrated 
in all five fetal lambs, with a median arterial concentra­
tion o f 18% (range 3-85% ) o f that in the ewe.
3.2. Blockade o f  serotonin-2 receptors by ketanserin
3.2.1. Serotonin-2 blockade in the ewe
Results are presented in Table 1A and Fig. 2. Intra­
venous administration o f ketanserin to  the ewe in a dose 
of 0.75 mg/kg, was followed by a variable reduction in 
maternal arterial pressure by an average o f  11% and an 
increase in uterine blood flow o f approximately 13% 
(P < 0.05); the effect on fetal arterial pressure was 
negligible. In the absence o f ketanserin, intravenous 
administration o f serotonin (20 pg/kg) to  the ewe was 
associated with a monophasic pressor response and 
caused a maximum increase in mean maternal arterial 
pressure o f 48%, a reduction in uterine blood flow of 
81%, and an increase in fetal arterial pressure o f  32%; all 
changes were highly significant (P < 0.001).
After intravenous adm inistration of ketanserin, 
serotonin had hardly any effect on maternal arterial 
pressure, but uterine blood flow still fell by approx­
imately 75% in all cases; the fall in uterine blood flow 
was similar to  that observed after serotonin in the ab­
sence o f ketanserin administration. Fetal arterial pres­
sure showed a variable and non-significant increase of 
approximately 15%.
3.2.2. Serotonin-2 blockade in the fe ta l lamb
Results are summarized in Table IB. Intravenous in-
Table 1
Peak maternal and fetal hemodynamic responses to intravenous administration of serotonin (20 ftg/kg) to the ewe (A) and to the fetal lamb (B), 
before and after ketanserin (0.75 mg/kg) (n = S)
Before ketanserin After ketanserin
Control values Changes after / ’-value 
serotonin
Control values Changes after P-value 
serotonin
A
Matemal arteria! pressure 106 ±  13 +51 ±  23 <0.001 94 ±  9 -7  ±  19 n.s.
(mmHg)
Uterine blood flow 134 ±  37 -108 ±  29 <0.001 151 ±  43 -110 ±  44 <0.001
(ml/min)
Fetal arterial pressure 65 ±  7 +21 ±  7 <0.001 59 ±  8 +9 ±  14 n.s.
(mmHg)
B
Matemal arterial pressure 99 ±  10 +8 ±  9 n.s. 101 ±  9 +16 ±  21 n.s.
(mmHg)
Uterine blood flow 166 ±  29 +8 db 21 n.s. 189 ±  16 -1 6  ±  19 n.s.
(ml/min)
Fetal arterial pressure 63 ±  10 +20 ±  8 <0.05 62 ±  11 +7 ±  6 n.s.
(mmHg)
Values are means ±  S.D. n.s., not significant (P >  0.05).
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Fig. 2. Circulatory changes induced by i.v. injection of 20 /¿g/kg 
serotonin into a single ewe before and after ketanserin blockade.
Fig. 3. Circulatory changes induced by i.v. injection ot 10 n%/kg 
phenylephrine into a single ewe before and after ketanserin blockade.
jection of serotonin (20 /tg/kg) into the fetal lamb caused 
a significant rise in fetal arterial pressure of 32%. The 
small changes observed in maternal arterial pressure and 
in uterine blood flow were variable and not statistically 
significant.
After administration of ketanserin, serotonin caused 
a small and non-significant increase in fetal arterial pres-
sure (11%); maternal arterial pressure and uterine blood 
flow were not significantly affected.
3.3. Blockade o f  a -1-adrenergic receptors by ketanserin
3.3.1. Alpha-1-adrenergic blockade in the ewe 
Results are presented in Table 2A and Fig. 3. In tra­
Table 2
Peak maternal and fetal hemodynamic responses to intravenous administration of phenylephrine (10 jig/kg) to the ewe (A) and to the fetal lamb 
(B), before and after ketanserin (0.75 mg/kg) (« = 5)
Before ketanserin After ketanserin
Control values Changes after / ’-value 
phenylephrine
Control values Changes after Z5-va lue 
phenylephrine
A
Matemal arterial pressure 
(mmHg)
108 ±  1 +38 ±  16 0.005 92 ±  17 +29 ± 8 0.001
Uterine blood flow 
(ml/min)
156 ± 13 -65 ±  53 0.01 163 ± 13 -75  ± 25 0.002
Fetal arterial pressure 
(mmHg)
B
67 ± 9 +5 ± 3 n.s. 54 ± 12 +8 ±  6 n.s.
Matemal arterial pressure 
(mmHg)
104 ±  8 +7 ± 10 n.s. 104 ±  9 0 ± 4 n.s.
Uterine blood flow 
(ml/min)
183 ±  40 -36  ± 15 0.02 186 ±  20 -10  ± 19 n.s.
Fetal arterial pressure 
(mmHg)
67 ±  10 +21 ± 10 0.001 67 ± 10 +7 ± 5 n.s.
n.s., not significant (P >  0.05).
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venous adm inistration o f  phenylephrine significantly 
increased maternal arterial pressure by 35%, and 
reduced uterine blood flow by 41%; fetal arterial pres­
sure showed a small and variable rise. Similar responses 
to phenylephrine were observed following ketanserin 
administration.
3.3.2. Alpha-1-adrenergic blockade in the fe ta l lamb
Results are presented in Table 2B. Phenylephrine in­
jection into the fetal lamb induced a significant increase 
in fetal arterial pressure o f approximately 31%. M ater­
nal arterial blood pressure did not change significantly, 
but uterine blood flow showed a significant fall o f  20%. 
After ketanserin injection into the fetal lamb, 
phenylephrine did not significantly affect fetal and ma­
ternal arterial pressures or uterine blood flow.
4. Discussion
In our experiments in the pregnant ewe, ketanserin 
appeared to be transferred across the placenta. Fetal 
ketanserin levels were low, with m arked variability, in­
dicating limited transfer with a large inter-individual 
variation. The disappearance o f ketanserin from m ater­
nal plasma in our sheep experiments, as judged from the 
median half-life o f 13 min, was similar to that observed 
in non-pregnant humans [16]. Intravenous adm inistra­
tion o f ketanserin in a single dose o f 0.75 mg/kg resulted 
in a small fall in maternal arterial pressure associated 
with a small increase in uterine arterial flow. Although 
these changes were statistically significant, they were 
variable and should be interpreted with care. We used 
normotensive ewes and maternal hemodynamic 
responses in conditions o f hypertension could be dif­
ferent. M aternal or fetal adm inistration o f ketanserin 
was not associated with changes in fetal hemodynamics. 
M aternal and fetal arterial blood gas samples showed 
normal values after ketanserin adm inistration to the ewe 
or the fetus. These results indicate that ketanserin in the 
single dose investigated has no deleterious effects on 
fetal condition.
We found that serotonin injection in the pregnant ewe 
was associated with a monophasic arterial pressor re­
sponse, vasoconstriction o f the uterine artery with a fall 
in uterine blood flow, and a rise in fetal arterial pressure.
Our observations are in agreement with those by Lang 
et al. [17], also in pregnant sheep, but contrary to the 
findings o f van Zwieten et al. [6], who observed a tri­
phasic response to intravenous injection o f serotonin in 
rats and other experimental animals. After blockade of 
the 5-HT-2-receptors with ketanserin, the arterial 
pressor response to  serotonin in the ewe and in the fetal 
lamb was completely inhibited while uterine blood flow 
decreased as before. Previous studies showed that con­
striction o f the uterine vasculature induced by 2,5- 
dimethoxy-4-methylamphetamine (DOM), a highly
selective 5-HT-2 agonist, can be completely inhibited by 
ketanserin [18,19]. The observation that in our experi­
ments ketanserin did not m odulate the uterine vascular 
response to serotonin suggests that in pregnancy, in 
addition to 5-HT-2 receptors, other receptors could be 
involved in the vasoconstrictor response o f the ovine 
uterine artery to exogenous serotonin.
Phenylephrine, a vasoconstrictor o f  sustained action 
mainly mediated by a-receptors, administered to  the 
ewe increased maternal arterial pressure and reduced 
uterine blood flow. In our experiments ketanserin, in the 
relatively low dose o f 0.75 mg/kg, did not inhibit the 
phenylephrine-induced pressor response in the ewe. In 
contrast, ketanserin in a much higher dose o f 10 mg/kg, 
as used by Nelson et al. [20], did show a significant a- 
blocking effect in sheep. In the fetal lamb, however, 
ketanserin clearly showed a-antagonist activity by 
blocking the rise in fetal arterial pressure induced by 
phenylephrine.
Phenylephrine administered to the fetal lamb not only 
caused a rise in fetal arterial pressure, but also a variable 
but significant fall in uterine blood flow. This was an un­
expected observation, for which we cannot present a 
logical explanation. The dose of 10 j*g/kg o f estimated 
fetal weight appears too low to cause an effective con­
centration in the maternal circulation after placental 
transfer and, indeed, no changes in maternal blood 
pressure were apparent.
In conclusion, our animal experiments have shown 
that ketanserin may prevent the serotonin-induced rise 
in maternal blood pressure, without an effect on a 
serotonin-induced reduction in uterine blood flow. If we 
assume that serotonin contributes to the maternal 
vasoconstriction that is characteristic o f hypertensive 
pregnancy [5], and if we extrapolate our findings in the 
pregnant ewe to the preeclamptic patient, our results 
suggest that ketanserin may reduce maternal hyperten­
sion without an effect on uterine blood flow.
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